Trifluoperazine dihydrochloride

• CAT Number: I003560
• CAS Number: 440-17-5
• Molecular Formula: C21H24F3N3S • 2HCl
• Molecular Weight: 480.4
• Purity: ≥95%
• Target: Autophagy
• Solubility: DMSO 88 mg/mL; Water 88 mg/mL
• Storage: 3 years -20C powder
• InChIKey: BXDAOUXDMHXPDI-UHFFFAOYSA-N

Trifluoperazine Dihydrochloride is a potent dopamine D2 receptor inhibitor used as an antipsychotic and an antiemetic.Target: Dopamine D2 ReceptorTrifluoperazine Dihydrochloride is a potent dopamine D2 receptor inhibitor used as an antipsychotic and an antiemetic. Trifluoperazine inhibited in a dose-dependent manner the stimulation of glycogenolysis, gluconeogenesis, and ureogenesis due to alpha 1-adrenergic stimulation in rat hepatocytes. Trifluoperazine is much more potent at alpha 1- than at alpha 2-adrenergic receptors [1]. Trifluoperazine was not clearly different in terms of /’no substantial improvement/’ (n=1016, 27 RCTs, RR 1.06 CI 0.98 to 1.14) or leaving the study early (n=930, 22 RCTs, RR 1.15 CI 0.83 to 1.58). Almost identical numbers of people reported at least one adverse event (60%) in each group (n=585, 14 RCTs, RR 0.99 CI 0.87 to 1.13), although trifluoperazine was more likely to cause extrapyramidal adverse effects overall when compared to low potency antipsychotics such as chlorpromazine (n=130, 3 RCTs, RR 1.66 CI 1.03 to 2.67, NNH 6 CI 3 to 121). One small study (n=38) found no clear differences between trifluoperazine and the atypical drug, sulpiride [2].

Reference

[1]. Huerta-Bahena, J., R. Villalobos-Molina, and J.A. Garcia-Sainz, Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol, 1983. 23(1): p. 67-70.

[2]. Marques, L.O., M.S. Lima, and B.G. Soares, Trifluoperazine for schizophrenia. Cochrane Database Syst Rev, 2004(1): p. CD003545.